Modulation of systemic and intestinal immune response by interleukin-2 therapy in gastrointestinal surgical oncology. Personal experience in the context of current knowledge and future perspectives

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 989-996

  Nespoli, Luca ^a   Uggeri, Fabio ^a   Romano, Fabrizio ^a   Nespoli, Angelo ^a   Brivo, Fernando ^b   Fumagalli, Luca ^c   Sargenti, Manuela ^d   Uggeri, Franco ^a   Gianotti, Luca ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b Bassini Hospital   (Italy)

^c A MANZONI HOSPITAL   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Colorectal cancer; Immunology; Interleukin 2; Intestine; Review; Surgery

Indexed keywords

CD11 ANTIGEN; CD123 ANTIGEN; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; VASCULOTROPIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; HUMAN; IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INTESTINE CELL; LOW DRUG DOSE; MELANOMA; NATURAL KILLER CELL; PHENOTYPE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SOFT TISSUE METASTASIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; INTESTINES;

EID: 84858764449     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Swann JB and Smyth MJ: Immune surveillance of tumors. J Clin Invest 117(5): 1137-1146, 2007. (Pubitemid 46718398)
2. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 3(11): 991-998, 2002. (Pubitemid 35363648)
3. Khong HT and Restifo NP: Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol 3(11): 999-1005, 2002. (Pubitemid 35363649)
4. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117(5): 1155-1166, 2007. (Pubitemid 46718400)
5. Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6(10): 715-727, 2006. (Pubitemid 44453458)
6. Chandra S and Chandra RK: Nutrition, immune response, and outcome. Prog Food Nutr Sci 10(1-2): 1-65, 1986. (Pubitemid 17031091)
7. Nespoli A, Gianotti L, Totis M, Bovo G, Nespoli L, Chiodini P and Brivio F: Correlation between postoperative infections and long-term survival after colorectal resection for cancer. Tumori 90(5): 485-90, 2004. (Pubitemid 39556798)
8. Law WL, Choi HK, Lee YM, Ho JW and Seto CL: Anastomotic leakage is associated with poor long-term outcome in patients after curative colorectal resection for malignancy. J Gastrointest Surg 11(1): 8-15, 2007.
9. Ni Choileain N and Redmond HP: Cell response to surgery. Arch Surg 141(11): 1132-40, 2006.
10. Menger MD and Vollmar B: Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch Surg 389(6): 475-484, 2004. (Pubitemid 40022444)
11. Hensler T, Hecker H, Heeg K, Heidecke CD, Bartels H, Barthlen W, Wagner H, Siewert JR and Holzmann B: Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 65(6): 2283-2291, 1997. (Pubitemid 27237311)
12. Brune IB, Wilke W, Hensler T, Holzmann B and Siewert JR: Downregulation of T helper 1 immune response and altered pro-inflammatory and anti-inflammatory T-cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 177(1): 55-60, 1999. (Pubitemid 29088998)
13. Mokart D, Capo C, Blache JL, Delpero JR, Houvenaeghel G, Martin C and Mege JL: Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 89(11): 1450-1456, 2002.
14. Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7): 1303-1310, 1996. (Pubitemid 26102328)
15. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT and Sirigu P: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104(6): 1246-1254, 2005. (Pubitemid 41278960)
16. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T-cells, recurrence and survival in epithelial ovarian cancer. N Eng J Med 348(3): 203-213, 2003. (Pubitemid 36077915)
17. + T-lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10(13): 4450-4456, 2004.
18. + T-cell infiltrations within esophageal carcinomas. Cancer Res 61(10): 3932-3936, 2001.
19. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-1964, 2006. (Pubitemid 44498003)
20. + T-cell count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possibile association with suppression of micrometastasis. Br J Cancer 91(9): 1711-1717, 2004.
21. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, Fleuren GJ and Kuppen PJ: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84(4): 493-501, 2004. (Pubitemid 41656477)
22. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Galon J: Effector memory T-cells, early metastasis, and survival in colorectal cancer. N Eng J Med 353(25): 2654-2666, 2005. (Pubitemid 41817714)
23. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M and Malesci A: CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10(9): 877-884, 2009.
24. Smith KA: Interleukin-2: inception, impact, and implications. Science 240(4856): 1169-1176, 1988.
25. + memory T-cells. Nature 41(7095): 890-893, 2006.
26. Hoyer KK, Dooms H, Barron L and Abbas AK: Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 226: 19-28, 2008.
27. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T and Neuwirt J: Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report. Cancer Immunol Immunother 14(3): 205-206, 1983. (Pubitemid 13117137)
28. Culliton BJ: FDA panel backs interleukin-2. Nature 355(6358): 287, 1992.
29. Shaker MA and Younes HM: Interleukin-2: evaluation of route of administration and current delivery systems in cancer therapy. J Pharm Sci 98(7): 2268-98, 2009.
30. Brivio F, Lissoni P, Perego M, Lissoni A and Fumagalli L: Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of post-operative complications. J Biol Regul Homeost Agents 15(4): 370-374, 2001. (Pubitemid 34162926)
31. Brivio F, Gilardi R, Bucocev R, Ferrante R, Rescaldani R, Vigorè R and Fumagalli L: Surgery-induced decline in circulating dendritic cells in operable cancer patients. A possible explanation of post-operative immunosuppression. Hepatogastroenterology 47(35): 1337-1339, 2000.
32. Brivio F, Lissoni P, Gilardi R, Ferrante R, Vigore' R, Curzi L, Uggeri F and Nespoli A: Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous pre-operative administration of IL-2 in operable cancer patients. J Biol Regul Homeost Agents 14(3): 200-203, 2000. (Pubitemid 32288254)
33. Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H and Uggeri F: Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol 14(4): 1295-1304, 2007. (Pubitemid 46536815)
34. Uggeri F, Caprotti R, Degrate L, Crippa S, Nobili C, Penati C and Romano F: Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. Hepatogastroenterology 56(91-92): 861-865, 2009.
35. Brivio F, Fumagalli L, Lissoni P, Nardone A, Nespoli L, Fattori L, Denova M, Chiarelli M and Nespoli A: Preoperative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C. Anticancer Res 26(1B): 599-603, 2006.
36. Brivio F, Lissoni P, Rovelli F, Nespoli A, Uggeri F, Fumagalli L and Gardani G: Effects of IL-2 pre-operative immunotherapy on surgery-induced changes in angiogenetic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 49(44): 385-387, 2002. (Pubitemid 34606558)
37. Brivio F, Fumagalli L, Lissoni P, Nardone A, Nespoli L, Fattori L, Denova M, Chiarelli M and Nespoli A: Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg 394(1): 115-121, 2009.
38. Bovo G, Brivio F, Brenna A, Fumagalli L, Perego P, Brivio F, Uggeri F, Lavorato F and Bratina G: Preoperative interleukin-2 immunotherapy induced eosinophilic infiltration in colorectal neoplastic stroma. Pathologica 87(2): 135-138, 1995.
39. Gianotti L, Sargenti M, Galbiati F, Nespoli L, Brivio F, Rescigno M and Nespoli A: Phenotype and function of dendritic cells and T-lymphocyte polarization in the human colonic mucosa and adenocarcinoma. Eur J Surg Oncol 34(8): 883-889, 2008.
40. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE and Bradley EC: Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 50(7): 2009-2017, 1990.
41. Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, Rescaldani R, Alderi G and Nociti V: Effects of a preoperative therapy with interleukin-2 on surgery induced lymphocytopenia in cancer patients. Oncology 49(3): 215-218, 1992.
42. Lappin MB and Campbell JD: The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev 14(4): 228-239, 2000. (Pubitemid 32096455)
43. Gianotti L, Fortis C, Braga M, Gentilini O, Vignali A and Di Carlo V: Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol 66(4): 244-247, 1997. (Pubitemid 28013698)
44. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000. (Pubitemid 30365397)
45. de Jong EC, Smits HH and Kapsenberg ML: Dendritic cell-mediated T-cell polarization. Springer Semin Immunopathol 26(3): 289-307, 2005.
46. Kelsall BL and Rescigno M: Mucosal dendritic cells in immunity and inflammation. Nat Immunol 5(11): 1091-1095, 2004. (Pubitemid 39549618)
47. Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A and Sallusto F: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for Th1 priming. Nat Immunol 5(12): 1260-5, 2004. (Pubitemid 41057741)
48. Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME and Lotze MT: Pharmacologic administration of interleukin-2. Ann NY Acad Sci 1182: 14-27, 2009.
49. Gooding R, Riches P, Dadian G, Moore J and Gore M: Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 72(2): 452-455, 1995.
50. Bernsen MR, Tang JW, Everse LA, Koten JW and Otter WD: Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat Rev 25(2): 73-82, 1999. (Pubitemid 29353667)
51. Jacobs JJ, Sparendam D and Den Otter W: Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 54(7): 647-654, 2005. (Pubitemid 40884160)
52. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M and Garbe C: Phase II trial of intralesional therapy with interleukin-2 in soft tissue melanoma metastases. Br J Cancer 89(9): 1620-1626, 2003. (Pubitemid 37464130)
53. Green DS, Bodman-Smith MD, Dalgleish AG and Fischer MD: Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156(2): 337-345, 2007. (Pubitemid 46095963)
54. Green DS, Dalgleish AG, Belonwu N, Fischer MD and Bodman-Smith MD: Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastastic melanoma. Br J Dermatol 159(3): 606-614, 2008.